Details

Autor(en) / Beteiligte

• Jang, D.H., Korea Testing and Research Institute for Chemical Industry, Gimpo, Republic of Korea
• Sung, H.J., Korea Testing and Research Institute for Chemical Industry, Gimpo, Republic of Korea
• Han, W.J., Ahn-Gook Pharmaceutical Co. Ltd., Seoul, Republic of Korea
• Kim, Y.J., Ahn-Gook Pharmaceutical Co. Ltd., Seoul, Republic of Korea
• Yoon, S.Y., Ahn-Gook Pharmaceutical Co. Ltd., Seoul, Republic of Korea
• Kim, S.Y., Ahn-Gook Pharmaceutical Co. Ltd., Seoul, Republic of Korea
• Jeong, J.H., Chungbuk Province College, Okcheon, Republic of Korea
• Hue, J.J., Chungbuk National University, Cheongju, Republic of Korea
• Nam, S.Y., Chungbuk National University, Cheongju, Republic of Korea
• Yun, Y.W., Chungbuk National University, Cheongju, Republic of Korea
• Lee, B.J., Chungbuk National University, Cheongju, Republic of Korea
• Kim, J.S., Chungbuk National University, Cheongju, Republic of Korea

Titel

Comparison of Intravenous versus Intranasal Administrations in Effectiveness of Ondansetron on Cisplatin-Induced Emesis in Ferrets

Ist Teil von

• Laboratory Animal Research, 2009, 25(3), , pp.219-224

Ort / Verlag

한국실험동물학회

Erscheinungsjahr

2009

Beschreibungen/Notizen

• This study was carried out to assess the potential of intranasal administration of ondansetron (a 5-HT₃ receptor antagonist, which antagonize the acute emetic response) in preventing cisplatin-induced emesis in the ferret. After intranasal administration of ondansetron at doses of 0.3 and 0.6 mg/kg, the peak plasma concentrations (Cmax) were 38 and 66.7 ng/mL, and attained at 13 and 23 min (Tmax) respectively. The intravenous (0.3 mg/kg) and intranasal (0.6 mg/kg) administrations of ondansetron significantly delayed the latency time to the first retching and vomiting. In acute phase of emesis during 24 hr, the number of vomits and retches were significantly reduced both in intravenous and intranasal administration groups. In delayed emesis (24-72 hr), intranasal administration of ondansetron at a higher dose of 0.6 mg/kg or intravenous injection of 0.3 mg/kg significantly reduced retching but not vomiting. Intranasal ondansetron, administered as 0.6 mg/kg dose, provided potency in antiemetic control comparable to intravenous ondansetron (0.3 mg/kg) in cisplatin-induced acute emesis, without well known side effects when injected via intravenously. These results suggest that intranasal administration of ondansetron can be an effective substitute for intravenous administration for the prevention of cisplatin-induced acute emesis.